IBL Tool - Digitale Bibliotheek

Digitale Bibliotheek

Sluiten

Tijdschrift beschrijving

Alle jaargangen van het bijbehorende tijdschrift

Alle afleveringen van het bijbehorende jaargang

Alle artikelen van de bijbehorende aflevering

418 gevonden resultaten

nr	titel	auteur	tijdschrift	jaar	jaarg.	afl.	pagina('s)	type
1	author index				27	S2	p. ii129-ii139	artikel
2	Editorial Board				27	S2	p. ii-iii	artikel
3	LBA-02 A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: first results from the CRITICS study	Verheij, M.			27	S2	p. ii140	artikel
4	LBA-03 Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial	Bruix, J.			27	S2	p. ii140	artikel
5	LBA-05 First-line FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC): the open-label, randomized phase 3 TAILOR trial	Qin, S.			27	S2	p. ii141	artikel
6	LBA-06 IMAB362: a novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancer	Al-Batran, S.E.			27	S2	p. ii141	artikel
7	LBA-01 Safety and efficacy of cobimetinib (cobi) and atezolizumab (atezo) in a Phase 1b study of metastatic colorectal cancer (mCRC)	Bendell, J.			27	S2	p. ii140	artikel
8	LBA-04 The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MSEC): efficacy and quality of life results	Bennouna, J.			27	S2	p. ii141	artikel
9	O-022 A multi-institutional phase 2 study of single agent nivolumab in previously treated metastatic squamous cell carcinoma of the anal canal (SCCA)	Morris II, V.			27	S2	p. ii126	artikel
10	O-013 A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC)	Pietrantonio, F.			27	S2	p. ii122	artikel
11	O-010 An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: compliance and safety of the phase III Japanese ACHIEVE trial	Eto, T.			27	S2	p. ii121	artikel
12	O-027 A pivotal phase 3 trial of MABp1 in advanced colorectal cancer	Hickish, T.			27	S2	p. ii128	artikel
13	O-016 A prognostic marker for colorectal cancer: combining analyses of ploidy and stroma	Fotheringham, S.			27	S2	p. ii124	artikel
14	O-015 Association between depth of response (DpR) and survival outcomes in RAS-wild-type (wt) patients with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI plus cetuximab once-every-2-weeks in the APEC study	Cheng, A.-L.			27	S2	p. ii123	artikel
15	O-007 Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study	Van Cutsem, E.			27	S2	p. ii120	artikel
16	O-017 Can single nucleotide variants in TGFBR1 and SMAD7 modify colorectal screening recommendations?	Mahon, G.			27	S2	p. ii124	artikel
17	O-024 Circulating tumor DNA extended RAS mutational analysis as a surrogate of mutational status of tumor samples in metastatic colorectal cancer and its impact on patient selection for anti-EGFR therapy	Grasselli, J.			27	S2	p. ii127	artikel
18	O-018 Clinical application of targeted next generation sequencing for colorectal cancer patients: a multicentric Belgian experience	Fontanges, Q.			27	S2	p. ii124	artikel
19	O-026 Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC): phase 2 results	Tabernero, J.			27	S2	p. ii127	artikel
20	O-005 Comparative molecular analyses of esophageal adenocarcinoma, esophageal squamous cell carcinoma, and gastric adenocarcinoma, and impact of molecular profile on outcome	Salem, M.			27	S2	p. ii119	artikel
21	O-019 Distant-relapse analysis of STAR-01, a randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer	Lonardi, S.			27	S2	p. ii125	artikel
22	O-004 Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine	Hubner, R.			27	S2	p. ii119	artikel
23	O-014 Evaluation of depth of response within a volumetric model in patients with metastatic colorectal cancer: results of the SIRFLOX study	Heinemann, V.			27	S2	p. ii123	artikel
24	O-008 Impact of chromogranin A, grade, and mitotic rate in small, non-functional pancreatic neuroendocrine tumors: q US population based study	Mirkin, K.			27	S2	p. ii120	artikel
25	O-020 Impact of surgical site experience on treatment outcomes of fixed-cT3 and cT4 rectal cancer patients in phase III study comparing preoperative radiochemotherapy and short-course radiotherapy with consolidation chemotherapy (Polish-II study)	Wyrwicz, L.			27	S2	p. ii125	artikel
26	O-003 Long-term outcome from the SCALOP trial: a multi-centre randomized phase II trial of gemcitabine or capecitabine-based chemoradiation (CRT) for locally advanced pancreatic cancer (LAPC)	Hurt, C.			27	S2	p. ii118	artikel
27	O-011 Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO	Antoniotti, C.			27	S2	p. ii121	artikel
28	O-009 NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate	Strosberg, J.			27	S2	p. ii121	artikel
29	O-023 Observational data outcomes of chemotherapy backbone for MSI – high metastatic colorectal cancer in molecular epidemiology of colorectal cancer in Israel	Shulman, K.			27	S2	p. ii126	artikel
30	O-012 Prognosis of lung metastases in patients with metastatic colorectal cancer: an ARCAD meta analysis	Henriques, J.			27	S2	p. ii122	artikel
31	O-006 Survival impact of histology for resectable gastric cancer: a multicenter US observation study	Greenleaf, E.			27	S2	p. ii119	artikel
32	O-021 Tailored strategy for locally-advanced rectal carcinoma: preliminary results of a phase II multicenter trial (GRECCAR 4)	Rouanet, P.			27	S2	p. ii126	artikel
33	O-001 The influence of multidisciplinary teams on diagnosis and treatment	Basta, Y.			27	S2	p. ii118	artikel
34	O-002 Utilization and trends in palliative therapy for stage IV pancreatic adenocarcinoma patients: a US population based study	Kulaylat, A.			27	S2	p. ii118	artikel
35	P-183 Abrogation of alcohol dehydrogenase-1B expression by CD90+ stromal cells supports tumor-promoting inflammation in colorectal cancer	Villéger, R.			27	S2	p. ii54	artikel
36	P-201 A Comparative Study for Effectiveness of Irreversible Electroporation Ablation according to Therapeutic Method: Colon Cancer Animal Model	Choi, H.S.			27	S2	p. ii58	artikel
37	P-032 A complete blood count as a prognostic marker in patients with metastatic colorectal cancer (mCRC)	Krakowska, M.			27	S2	p. ii9	artikel
38	P-083 Adjuvant chemotherapy as a way to improve the results of surgical treatment of gastric cancer	Djuraev, F.			27	S2	p. ii25	artikel
39	P-099 Advanced hepatocellular cancer treated with sorafenib - analysis of prognostic factors for patients' survival: single institution experience	Nowara, E.			27	S2	p. ii29	artikel
40	P-088 A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment	Yin, Y.			27	S2	p. ii26	artikel
41	P-028 Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG)	Souglakos, J.			27	S2	p. ii9	artikel
42	P-017 Analysis of microRNA expression in Gastroenteropancreatic Neuroendocrine Tumor	Vega Neira, S.J.			27	S2	p. ii5	artikel
43	P-222 Analysis of tumour contours and radiotherapy planning of “on-trial” patients undergoing chemoradiotherapy (CRT) in SCALOP trial: does pre-trial Radiotherapy Quality Assurance (RTQA) improve the quality of “on-trial” radiotherapy?	Fokas, E.			27	S2	p. ii64	artikel
44	P-229 An Evaluation Based on a Systematic Review of Epidemiologic Evidence of Colorectal Cancer Risk among the Alcohol Consuming Indian Population	Mishra, A.			27	S2	p. ii66	artikel
45	P-131 An international patient-centered outcome measurement set for colorectal cancer	Zerillo, J.			27	S2	p. ii38	artikel
46	P-212 An investigation of the association between sarcopenia and post-operative morbidity and mortality in patients with gastric cancer	O'Brien, S.			27	S2	p. ii61	artikel
47	P-265 Anterior versus conventional approach for resection of large right lobe hepatocellular carcinoma	Fakhry, H.			27	S2	p. ii77	artikel
48	P-144 Anti –EGRF Monoclonal Antibodies and Surgery of Metastases in the Treatments of Metastatic Colorectal Cancer (mCRC)	Kit, O.			27	S2	p. ii42	artikel
49	P-106 Anxiety and depression as predictive factors for quality of life in patients with newly diagnosed advanced gastrointestinal cancer	Kim, S.T.			27	S2	p. ii131	artikel
50	P-087 A phase II study of a combination treatment of alternate-day S-1 and lentinan as first-line chemotherapy for unresectable or recurrent gastric cancer	Yoshino, S.			27	S2	p. ii26	artikel
51	P-157 A phase II study of XELOX and Cetuximab (Erbitux) as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (FLEET2)	Iwamoto, S.			27	S2	p. ii46	artikel
52	P-104 A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer	Kim, H.M.			27	S2	p. ii30	artikel
53	P-049 A population study of correlation between the treatment rate for monoclonal antibodies (Mabs) and mortality rate in patients with metastatic colorectal cancer (mCRC) in Russia	Fedyanin, M.			27	S2	p. ii15	artikel
54	P-277 A prospective, observational trial to assess the safety and efficacy of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice (CORRELATE)	Michel, Ducreux			27	S2	p. ii80	artikel
55	P-285 A randomized, double-blind, placebo-controlled Phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)	Andrew, Zhu			27	S2	p. ii83	artikel
56	P-014 Are RHOA, CSNK1A1, DVL2, FZD8 and LRP5 Genes Novel Biomarkers in the conversion from Intestinal Metaplasia to Gastric Cancer?	Demirci, U.			27	S2	p. ii4	artikel
57	P-203 Assessing intratumor heterogeneity and evolutionary distance in exome sequencing of colon cancer	Popper, U.			27	S2	p. ii59	artikel
58	P-026 Assessment of lymph nodes for micrometastasis in high risk patients with colorectal cancer	Botiralieva, G.			27	S2	p. ii8	artikel
59	P-133 Assessment of sexual dysfunction in rectal cancer survivors	Rodrigues, J.			27	S2	p. ii39	artikel
60	P-018 Assessment of therapeutic potential of arsenic trioxide in the management of human hepatocellular carcinoma	Dugo, E.			27	S2	p. ii6	artikel
61	P-200 A study on response for irreversible electroporation of colon cancer cell using multiphoton microscopy	Keum, B.			27	S2	p. ii58	artikel
62	P-266 Benefits, in cirrhotic patient, of laparoscopic resection for malignant tumor. a retrospective study with propensity score analysis	Le Roux, F.			27	S2	p. ii77	artikel
63	P-064 Bevacizumab with chemodoublet as conversion-to-resectability therapy for patients with liver metastases of colorectal cancer	Ristic, M.			27	S2	p. ii20	artikel
64	P-170 Biweekly S-1 and nab-paclitaxel as first-line chemotherapy in patients with unresectable or recurrent gastric cancer	Yang, L.			27	S2	p. ii50	artikel
65	P-057 Body Composition (BC), beyond Body Mass Index (BMI) and sarcopenia, has a major prognostic impact on patients with refractory advanced Colorectal Cancer (aCRC)	Van Bogaert, C.			27	S2	p. ii17	artikel
66	P-027 Cancer stem cells marker CD44 and Notch activation predict unfavorable prognosis in metastatic colon cancer patients treated with anti VEGF-therapy	Negri, F.V.			27	S2	p. ii8	artikel
67	P-178 Capecitabine and temozolomide (CAPTEM) in patients with advanced neuroendocrine tumors: the experience of a Portuguese cancer center	Chaves, A.			27	S2	p. ii53	artikel
68	P-024 Carcinoembryonic antigen (CEA) and the carcinoma antigen 19-9 (CA 19-9) together in early diagnosis of Stage I-II colorectal adenocarcinoma. A case-control study	Lumachi, F.			27	S2	p. ii7	artikel
69	P-012 CCL2 expression is correlated with Snail expression and affects the prognosis of patients with gastric cancer	Zhang, J.			27	S2	p. ii4	artikel
70	P-219 Celiac ganglion block for abdominal cancer pain, CT guided approach	Bessar, A.			27	S2	p. ii63	artikel
71	P-068 Cetuximab in addition to oxaliplatin, fluorouracil and radiotherapy for patients with esophageal cancer treated without surgery	Alexandersson von Döbeln, G.			27	S2	p. ii21	artikel
72	P-167 Cetuximab rechallenge in metastatic colorectal cancer patients	Nogueira, A.			27	S2	p. ii49	artikel
73	P-119 Chemoradiotherapy versus chemotherapy alone for unresectable locally advanced pancreatic cancer: a retrospective cohort study	Maruki, Y.			27	S2	p. ii35	artikel
74	P-217 Chemoradiotherapy with Image-Guided Volumetric Modulated Arc Therapy (IG-VMAT) and Image-Guided Intensity Modulated Radiotherapy (IG-IMRT) to treat Squamous Anal Cancer	Athmanathan, S.			27	S2	p. ii63	artikel
75	P-163 Choice of first line treatment and survival in metastatic colorectal cancer – a retrospective analysis	Oliveira, A.			27	S2	p. ii48	artikel
76	P-244 Cholangiocarcinoma: a retrospective analysis of our experience in diagnosis, prognostic factors, staging and treatment	Inga, E.			27	S2	p. ii70	artikel
77	P-241 Cigarette smoking as a risk factor for the development of and mortality from hepatocellular carcinoma; an updated systematic review of 81 epidemiological studies	Abdel-Rahman, O.			27	S2	p. ii69	artikel
78	P-016 Circulating mRNA expression of CD133, SNAIL, ZEB1 and ZHX as biomarkers in gastric and esophageal cancer	Longo Muñoz, F.			27	S2	p. ii5	artikel
79	P-220 Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer	Goto, Y.			27	S2	p. ii64	artikel
80	P-123 Clinical experience of the efficacy and safety of two FOLFIRINOX variants for inoperable pancreatic cancer	Magri, C.			27	S2	p. ii36	artikel
81	P-086 Clinical outcome after endoscopic submucosal dissection for early gastric cancer of absolute and expanded indication; Retrospective Single Center Study	Eun, H.S.			27	S2	p. ii26	artikel
82	P-071 Clinical relevance of histologic subtype in locally advanced esophageal carcinoma treated with preoperative chemoradiotherapy followed by surgery	Saigí, M.			27	S2	p. ii22	artikel
83	P-146 Colorectal cancer patients with lung-only metastases have a favorable prognosis irrespective of treatment	Gadot, M.			27	S2	p. ii43	artikel
84	P-238 Colorectal cancer screening: understanding the patients' perspective	Brewer, T.			27	S2	p. ii68	artikel
85	P-154 Combined oxaliplatin, irinotecan and fluorouracil as a rescue regimen for heavily pretreated metastatic colorectal cancer patients	Dos Santos Fernandes, G.			27	S2	p. ii45	artikel
86	P-227 Comparative characteristics of somatic mutations in the KRAS gene in patients with colorectal cancer the South of Russia	Kit, O.			27	S2	p. ii66	artikel
87	P-215 Comparative planning of volumetric modulated arc therapy versus intensity modulated radiation therapy and proton beam therapy in anal cancer	Hansen, J.			27	S2	p. ii62	artikel
88	P-237 Comparison of adenoma detection by polypectomy during both insertion and withdrawal versus only withdrawal of colonoscopy: a randomized, controlled multicenter trial	Ji, J.-S.			27	S2	p. ii68	artikel
89	P-007 Comparison of methods for measuring total cell-free DNA and KRAS mutations in plasma from metastatic colorectal cancer patients	Demuth, C.			27	S2	p. ii2	artikel
90	P-090 Comparison of progression-free survival in gastric cancer patients receiving neoadjuvant chemotherapy alone versus chemotherapy plus concurrent chemoradiotherapy: a randomized, multi-center phase III clinical trial (in progress)	Haddad, P.			27	S2	p. ii27	artikel
91	P-062 Correlation of histological Tumor Regression Grading (TRG) with radiological response and long-term outcome after preoperative chemotherapy for Colorectal Liver Metastases: a propensity score matching analysis	Inada, R.			27	S2	p. ii19	artikel
92	P-111 Correlation of Mitotic Index and Ki-67 and Their Impacts on Survival of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at Ramathibodi Hospital	Dejthevaporn, T.			27	S2	p. ii33	artikel
93	PD-008 Adding ramucirumab to second-line irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) treatment for metastatic colorectal carcinoma (mCRC): resource utilization data from RAISE, a global, randomized, double-blind, multicenter phase 3 study	Kisro, J.			27	S2	p. ii104	artikel
94	PD-012 Analysis of patients ≥75 years in the open-label phase 3b CONSIGN trial of regorafenib in previously treated metastatic colorectal cancer (mCRC)	Van Cutsem, E.			27	S2	p. ii106	artikel
95	PD-003 Analysis of single-nucleotide polymorphisms (SNPs) in the phase 3 CORRECT trial of regorafenib vs placebo in patients with metastatic colorectal cancer (mCRC)	Lambrechts, D.			27	S2	p. ii102	artikel
96	PD-031 An exploratory study-level meta-analysis assessing the impact of early tumour shrinkage on overall survival in patients with RAS wild-type metastatic colorectal cancer receiving first-line treatment in three randomised panitumumab trials	Rivera, F.			27	S2	p. ii114	artikel
97	PD-017 A population-based study of gastric adenocarcinoma in Central Norway 2001–2011	Bringeland, E.A.			27	S2	p. ii108	artikel
98	PD-019 ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA)	Mazzaferro, V.			27	S2	p. ii109	artikel
99	PD-021 A single centre experience of the prognostic variables in hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization	Aravind, P.			27	S2	p. ii109	artikel
100	PD-010 Association between chemotherapy-induced neutropenia at 1-month and overall survival in patients receiving TAS-102 for metastatic colorectal cancer	Kotani, D.			27	S2	p. ii105	artikel
101	PD-029 Baseline carcinoembryonic antigen (CEA) as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma (mCRC) phase 3 trial	Yoshino, T.			27	S2	p. ii113	artikel
102	PD-027 BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (AIO KRK-0306)	Stintzing, S.			27	S2	p. ii112	artikel
103	PD-016 Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+ esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ)	Ryan, D.P.			27	S2	p. ii108	artikel
104	PD-007 CXCR4, CXCR7 and CXCL12 expression is not a prognostic predictive factor in patients with resected pancreatic cancer - results from the CONKO-001 trial	Striefler, J.			27	S2	p. ii104	artikel
105	PD-035 Efficacy and safety of second-line irinotecan based chemotherapy in early relapse patients with gastric cancer after adjuvant chemotherapy: exploratory subgroup analysis of TRICS trial	Nishikawa, K.			27	S2	p. ii115	artikel
106	P-015 Detection of gene сopy number variation as predictive markers for metastases in patients with gastric cancer	Kit, O.			27	S2	p. ii5	artikel
107	PD-038 Exposure-Response relationship of second-line ramucirumab in East Asian patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study	Kim, T.Y.			27	S2	p. ii116	artikel
108	PD-006 Final analysis of stage 1 data from a randomized phase 2 study of PEGPH20 plus nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients, utilizing Ventana companion diagnostic assay	Hingorani, S.			27	S2	p. ii103	artikel
109	PD-014 Final survival results and onset of neutropenia as an indicator of therapeutic effect in phase 2 of TAS-102 vs placebo with metastatic colorectal cancer (J003-10040030)	Yoshino, T.			27	S2	p. ii107	artikel
110	PD-013 Final survival results of a multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer patients refractory to standard therapies (C-TASK FORCE)	Yoshino, T.			27	S2	p. ii106	artikel
111	PD-022 FOLFOXIRI as primary treatment for locally advanced unresectable pancreatic cancer (LAPC): a prospective study	Vivaldi, C.			27	S2	p. ii109	artikel
112	PD-034 Heterogeneity in the first-line treatment of patients with advanced or metastatic gastric cancer in the US	Abrams, T.			27	S2	p. ii115	artikel
113	P-213 Different imaging findings of primary HCC in CT after locoregional treatment	Bessar, A.			27	S2	p. ii62	artikel
114	P-040 Dihydropyrimidine Dehydrogenase (DPD) and Thymidylate Synthase (TYMS) Germline Pharmacogenomics Role in Predicting Fluoropyrimidines Toxicity in Patients with Gastrointestinal (GI) Malignancies	Khushman, M.			27	S2	p. ii12	artikel
115	P-074 Distant outcome of patients with locally advanced unresectable and metastatic esophageal cancer after multimodality treatment	Gruia, I.			27	S2	p. ii23	artikel
116	PD-032 Is there an impact of the number of metastases in the outcome of potentially resectable metastatic colorectal cancer patients receiving bevacizumab-based regimen in 1st line? Results of the PICASSO study	Metges, J.-P.			27	S2	p. ii114	artikel
117	PD-004 Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study	Marmorino, F.			27	S2	p. ii103	artikel
118	PD-036 Maintenance chemotherapy or observation alone following gemcitabine-platinum combination palliative chemotherapy in locally advanced and/or metastatic gallbladder cancer - a single tertiary care centre experience in south Asia	Pinninti, R.			27	S2	p. ii116	artikel
119	P-199 Dosing first cycle of chemotherapy in colorectal cancer: is BSA used for everybody?	Una Cidon, E.			27	S2	p. ii58	artikel
120	PD-030 Prospective non-interventional study to collect data on the use of bevacizumab and conventional chemotherapy for the treatment of previously untreated metastatic colorectal cancer in patient's ≥70 years	Van Cutsem, E.			27	S2	p. ii113	artikel
121	PD-025 RECOURSE trial: impact of adverse events on quality of life and duration of TAS-102 (trifluridine and tipiracil) treatment	Tabernero, J.			27	S2	p. ii111	artikel
122	PD-005 Response and resistance factor candidates to HER2 targeted therapy in gastric cancer (GC)	Lordick, F.			27	S2	p. ii103	artikel
123	PD-002 Response to chemotherapy and prognosis in metastatic colorectal cancer with deficient mismatch repair	Alex, A.			27	S2	p. ii102	artikel
124	PD-028 Retrospective analysis of impact of Köhne prognostic category and BRAF mutation status on survival in patients with RAS wild-type metastatic colorectal cancer treated with second-line FOLFIRI with/without panitumumab	Peeters, M.			27	S2	p. ii112	artikel
125	PD-024 Retrospective analysis of quality of life and early tumour shrinkage during first-line FOLFOX4 ± panitumumab in RAS wild-type metastatic colorectal carcinoma	Siena, S.			27	S2	p. ii110	artikel
126	PD-033 Right-sided colon cancer is associated with increased frequency of KRAS mutation and with a poor outcome in patients with metastatic disease treated in the first line with bevacizumab and chemotherapy	Ostrizkova, L.			27	S2	p. ii114	artikel
127	PD-040 Risk assessment for gastrointestinal cancers in patients with family history of gastrointestinal cancer: Multi-center interim analysis study in the Republic of Korea	Chung, J.W.			27	S2	p. ii117	artikel
128	PD-018 Risk factors for metachronous gastric carcinoma development after endoscopic resection of gastric dysplasia	Moon, H.S.			27	S2	p. ii108	artikel
129	PD-039 Role of adjuvant radiotherapy following neo-adjuvant chemotherapy (NACT) and surgery in oesophageal cancer – a multi-centre retrospective cohort study	Teoh, S.			27	S2	p. ii117	artikel
130	PD-023 Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy	Chen, L.-T.			27	S2	p. ii110	artikel
131	PD-011 Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC)	Mahalingam, D.			27	S2	p. ii105	artikel
132	PD-009 Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies	Casagrande, M.			27	S2	p. ii104	artikel
133	PD-026 Survival outcomes in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) classified by Köhne prognostic category and BRAF mutation status: retrospective analysis of the PRIME study	Köhne, C.-H.			27	S2	p. ii111	artikel
134	PD-015 The prognostic role of tumour regression grade after neoadjuvant chemotherapy in patients with resectable gastro-oesophageal adenocarcinoma	Tin, A.			27	S2	p. ii107	artikel
135	PD-037 The relationship of high neutrophil-to-lymphocyte ratio to disease-free survival in colorectal cancer	Mouchli Mohamad, A.			27	S2	p. ii116	artikel
136	PD-020 Tolerability and activity of second-line tepotinib, a potent and highly selective c-MET inhibitor, in patients with advanced hepatocellular carcinoma previously treated with sorafenib	Faivre, S.			27	S2	p. ii109	artikel
137	PD-001 Total cell-free DNA level in plasma as strong prognostic marker in metastatic colorectal cancer	Spindler, K.-L.			27	S2	p. ii102	artikel
138	P-094 Early and long-term outcomes of gastric cancer patients treated with perioperative chemotherapy and radical surgery in a single cancer center	Viapiana, P.			27	S2	p. ii28	artikel
139	P-175 Effectiveness of sorafenib in the treatment of hepatocellular carcinoma	Salamanca, P.			27	S2	p. ii52	artikel
140	P-047 Effectiveness of TACE as bridge therapy for liver transplant in hepatocellular carcinoma	Ribeiro, C.			27	S2	p. ii14	artikel
141	P-063 Effect of age on treatment effect and tolerability of SIRT when added to mFOLFOX chemotherapy in patients with metastatic colorectal cancer (mCRC) – results from the SIRFLOX study	van Hazel, G.			27	S2	p. ii19	artikel
142	P-191 Effects of anxiety and depression on patients for information following diagnosis of colorectal cancer	Heras, P.			27	S2	p. ii56	artikel
143	P-206 Effects of eribulin mesilate for tumor progression and fibrosis in gastric cancer	Kurata, T.			27	S2	p. ii60	artikel
144	P-165 Efficacy and toxicity of FOLFIRI / aflibercept in second line colorectal cancer in real life population, retrospective study. Does first line matter?	Fernandez Montes, A.			27	S2	p. ii49	artikel
145	P-110 Efficacy of percutaneous transhepatic gallbladder drainage for acute cholecystitis in patients with unresectable Klatskin tumor	Kang, D.H.			27	S2	p. ii32	artikel
146	P-060 Endoscopic colorectal stenting for malignant large bowel obstruction comparing to surgery	Kang, D.H.			27	S2	p. ii18	artikel
147	P-107 Epidemiology of lymphomas involving the gastro intestinal tract: a multi center retrospective study from South Indian continent	Rathnam, K.			27	S2	p. ii131	artikel
148	P-254 Esophagectomy with cervical anastomosis has a greater need for intervention for dysphagia than intrathoracic anastomosis	Shlomi, M.			27	S2	p. ii74	artikel
149	P-189 Evaluation of short-term quality of life changes after surgery in elderly patients with colorectal cancer using the Medical Outcomes Study short form (MOS-SF-36) questionnaire	Lumachi, F.			27	S2	p. ii55	artikel
150	P-136 Evolution of efficacy and safety of cetuximab with the determination of RAS status in Metastatic Colorectal Cancer (mCRC) elderly patients	Metges, J.-P.			27	S2	p. ii40	artikel
151	P-142 Experience with Aflibercept as a second line chemotherapy in metastatic colorectal cancer	González-Flores, E.			27	S2	p. ii41	artikel
152	P-003 Extended Mutational Profiling for Metastatic Colorectal Cancer (CRC): beyond RAS Molecular Spectrum of KRAS-NRAS-BRAF and PI3K in Cancer Colorectal	Otero, S.			27	S2	p. ii1	artikel
153	P-077 Factors influencing nutritional status after Curative Gastrectomy for Gastric Cancer	Wang, T.-J.			27	S2	p. ii24	artikel
154	P-271 Feasibility of neoadjuvant chemotherapy with modified FOLFOX6 (combination chemotherapy of infusional 5-FU/l-Leucovorin and intermittent oxaliplatin) with bevacizumab in patients with locally advanced lower rectal cancer	Kosugi, C.			27	S2	p. ii78	artikel
155	P-147 Final analysis: phase II trial of Irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC: HGCSG0902. -comparison of administration interval in cetuximab treatment	Yuki, S.			27	S2	p. ii43	artikel
156	P-275 First-line pembrolizumab versus investigator-choice chemotherapy for mismatch repair–deficient or microsatellite instability–high metastatic colorectal carcinoma: randomized, phase 3 KEYNOTE-177 study	Luis, Diaz			27	S2	p. ii80	artikel
157	P-039 5-Fluorouracil Degradation Rate in Patients with Recurrent Gastrointestinal Cancer Treated with Metronomic Capecitabine	Roberto, M.			27	S2	p. ii12	artikel
158	P-125 FOLFIRINOX in borderline resectable pancreatic carcinoma	Una Cidon, E.			27	S2	p. ii37	artikel
159	P-161 5-FU based chemotherapy with Bevacizumab in synchronous metastatic colorectal cancer patients with bleeding primary tumor	Gruenberger, B.			27	S2	p. ii47	artikel
160	P-196 Gastrointestinal stromal tumors: Fifteen years of experience in a Portuguese Hospital Centre	Lopes, S.			27	S2	p. ii57	artikel
161	P-124 Gemcitabine-induced pseudocellulitis in patients with pancreatic adenocarcinoma or cholangiocarcinoma	Una Cidon, E.			27	S2	p. ii27	artikel
162	P-120 Gemcitabine + nab-paclitaxel as first-line chemotherapy for Japanese patients with advanced pancreatic cancer in real-world clinical practice: a retrospective study	Yamaguchi, T.			27	S2	p. ii35	artikel
163	P-288 Global Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Compare Efficacy and Safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Plus nab-Paclitaxel and Gemcitabine vs. Placebo Plus nab-Paclitaxel and Gemcitabine	Margaret, Tempero			27	S2	p. ii84	artikel
164	P-245 Growing incidence of pancreatic neuroendocrine tumours (PNET) in Czech Republic	Barkmanova, J.			27	S2	p. ii71	artikel
165	P-180 Health-related quality of life in patients with metastatic pancreatic cancer	Picozzi, V.			27	S2	p. ii53	artikel
166	P-248 Helicobacter pylori translocation to the regional lymph nodes in patients with gastric carcinoma	Viapiana, P.			27	S2	p. ii71	artikel
167	P-273 Hepatectomy followed by adjuvant chemotherapy with capecitabine plus oxaliplatin for three months for liver metastases from colorectal cancer: a multicenter phase 2 study	Hironaga, Satake			27	S2	p. ii79	artikel
168	P-289 Hepatic arterial infusion chemotherapy for unresectable liver metastases of colorectal cancer: a multicenter retrospective study	Lim, A.			27	S2	p. ii84	artikel
169	P-097 Hepatic artery embolization (HAE) in hepatocellular and gastroenteropancreatic neuroendocrine tumors at Instituto Oncologico Nacional, Panama	Castillo-Fernandez, O.			27	S2	p. ii29	artikel
170	P-118 Histopathological diagnoses of pancreatic cancer with endoscopic ultrasound guided fine needle biopsy (EUS-FNAB)	Byrne, R.			27	S2	p. ii35	artikel
171	P-235 How often does the patient repeat screening colonoscopy? a study for personalized recommendation of screening colonoscopy interval	Kim, E.S.			27	S2	p. ii67	artikel
172	P-006 Hypermethylation of APC, CDH13, MLH1, MGMT, P16 and RASSF1A promoter regions in patients with colorectal cancer	Kit, O.			27	S2	p. ii2	artikel
173	P-041 IKAROS: a potential prognostic marker in pancreatic ductal adenocarcinoma	Cruz Ramos, M.			27	S2	p. ii12	artikel
174	P-004 Immunohistochemical Expression of LRG5 and CD44 in Colorectal Polyps and Adenocarcinomas: Implications for Carcinogenesis	Yildiz, D.			27	S2	p. ii1	artikel
175	P-130 Impact of age on efficacy of neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC)	Calderillo, G.			27	S2	p. ii38	artikel
176	P-160 Impact of KRAS mutation on patterns of metastasis in a series of colorectal cancer patients	Domenech Viñolas, M.			27	S2	p. ii47	artikel
177	P-149 Impact of sequence of biologic therapies on overall survival (OS) in patients with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC): an exploratory, retrospective pooled analysis	Sobrero, A.			27	S2	p. ii44	artikel
178	P-234 Incidence of Sarcopenia and its relationship with Body Mass Index in colorectal cancer patients	Alivizatos, V.			27	S2	p. ii67	artikel
179	P-080 Incidence of thrombo-embolism (TE) during neo-adjuvant chemotherapy in patients (pts) with oesophago-gastric adenocarcinoma (OGC): implications for surgery and survival	Rulach, R.			27	S2	p. ii24	artikel
180	P-194 Inflammatory cytokines of rheumatoid arthritis (RA) and gastrointestinal cancer (GIC)	Davidhi, G.			27	S2	p. ii56	artikel
181	P-116 In Gastrointestinal' cancers, patients perspectives on palliative chemotherapy: a prospective study	Khatri, P.			27	S2	p. ii34	artikel
182	P-009 Inhibition of Gastrointestinal Neuroendocrine Tumor by A New Marker of Normal Neuroendocrine Cells	Pan, B.			27	S2	p. ii3	artikel
183	P-228 Inhibitory effect of Lactobacillus helveticus SBT2171 on the proliferation of colorectal tumor cells and the action mechanisms	Baba, K.			27	S2	p. ii66	artikel
184	P-172 Initial experience of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for treatment of peritoneally disseminated gastric cancer	Khomyakov, V.			27	S2	p. ii51	artikel
185	P-182 Institution experience of FOLFIRINOX chemotherapy in advanced pancreatic cancer	Haddadin, Y.			27	S2	p. ii54	artikel
186	P-076 Integrating CROSS – style chemotherapy regime into higher doses of radiation for the radical treatment of localized oesophageal carcinoma in patients with borderline fitness	Lim Pei, S.			27	S2	p. ii23	artikel
187	P-138 Is HER2 positivity gastric cancer good prognostic sign? - Our experiences	Vještica, M.			27	S2	p. ii40	artikel
188	P-264 Is laparoscopic approach an option in resection of advanced gastric cancer?	Castro, B.			27	S2	p. ii76	artikel
189	P-162 Is Resection the Only Choice for the Treatment of Bilobar Colorectal Cancer Metastases?	Chiappa, A.			27	S2	p. ii48	artikel
190	P-093 Is there a role of adjuvant radiotherapy in patients with primary resectable gastric cancer?	Trifanescu, O.			27	S2	p. ii28	artikel
191	P-282 JAVELIN Gastric 300: Phase 3 trial of avelumab (anti-PD-L1 antibody) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for advanced gastric or gastroesophageal junction cancer	Eric, Van Cutsem			27	S2	p. ii82	artikel
192	P-281 JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1 antibody) maintenance therapy vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer	Julien, Taieb			27	S2	p. ii81	artikel
193	P-001 Jointly alterations of voltage-gated Na+ channel SCN5A and E-cadherin genes may impact tumor cell proliferation in human colorectal cancer	Tuncel, H.			27	S2	p. ii1	artikel
194	P-259 Laparoscopic gastrectomy: our technique, complications and long-term oncological results	Baydo, S.			27	S2	p. ii75	artikel
195	P-256 Laparoscopic uncut Roux-en-Y anastomosis in the distant gastrectomy for gastric cancer: a report of 92 patients	Xu, Z.			27	S2	p. ii74	artikel
196	P-263 Laparoscopic versus open distal gastrectomy for gastric cancer: a single-center case-control study	Castro, B.			27	S2	p. ii76	artikel
197	P-224 Locally advanced rectal cancer: a single institution experience	Dueñas Cid, N.			27	S2	p. ii65	artikel
198	P-150 Locoregional therapy in liver dominant metastatic colorectal cancer having failed standard drug therapy: Outcome and prognostic parameters in 133 consecutive patients	Pluntke, S.			27	S2	p. ii44	artikel
199	P-036 Long Interspersed Nuclear Element (LINE)-1 Methylation Level as a Molecular Marker of Early Gastric Cancer	Chung, W.C.			27	S2	p. ii11	artikel
200	P-067 Long term results of a prospective study of dose escalated volumetric modulated arc radiotherapy with concurrent chemotherapy in inoperable squamous cell carcinoma of esophagus	Chilukuri, S.			27	S2	p. ii21	artikel
201	P-046 Low-dose paclitaxel suppresses the induction of M2 macrophages in gastric cancer	Yamaguchi, T.			27	S2	p. ii14	artikel
202	P-137 Macrophage coculture enhanced invasion of gastric cancer cells via FOXQ1 pathway	Zhang, J.			27	S2	p. ii40	artikel
203	P-209 Maintenance BEZ235 treatment following BEZ235 and radiation treatment prolongs the therapeutic effect in colorectal cancer	Wei Ming, F.			27	S2	p. ii60	artikel
204	P-109 MALT Lymphoma – Always a good prognosis?	Garcia, A.			27	S2	p. ii32	artikel
205	P-187 Management of chemo-induced nausea/vomiting (CINV) in medical oncology department Hassan II University of Fez (Morocco)	Ouahbi, H.			27	S2	p. ii55	artikel
206	P-255 "Many ways to skin gastric cancer" - Robotic versus laparoscopic versus open gastrectomy	Kakiashvili, E.			27	S2	p. ii74	artikel
207	P-033 Metabolic analysis of advanced Colorectal Cancer Tissues Using Two-Dimensional NMR Spectroscopy	Kim, S.			27	S2	p. ii10	artikel
208	P-038 MET activation via exon 14 skipping mutations (METex14del): gastrointestinal prevalence and sensitivity to MET inhibitor AMG337	Cecchi, F.			27	S2	p. ii11	artikel
209	P-145 Metastases resection following FOLFIRI-aflibercept in refractory patients to first-line chemotherapy: safety and efficacy analysis	Muñoz, A.			27	S2	p. ii42	artikel
210	P-286 Metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel (nab-P), bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer (MPC): an open-label, multicenter, single-arm, phase 1/2 study	Vincent, Picozzi			27	S2	p. ii83	artikel
211	P-139 Monitoring of erlotinib plasma concentrations after long time administration of 100 mg in advanced pancreatic cancer patients	Sahmanovic, A.			27	S2	p. ii41	artikel
212	P-242 Mortality trend for hepatocellular carcinoma in Albania: a hepatitis B virus endemic area	Kraja, F.			27	S2	p. ii69	artikel
213	P-095 MSCMCC gastric cancer cohort: indirect comparison between adjuvant chemoradiation and perioperative chemotherapy in gastric cancer patients in a referral site	Mydlowska, M.			27	S2	p. ii28	artikel
214	P-230 Muir-Torre Syndrome diagnostic and screening. a single center experience	Macías, R.			27	S2	p. ii67	artikel
215	P-253 Multimodal analgesia combined with epidural anesthesia and intravenous administration of acetaminophen in perioperative management of esophagectomy using modified ERAS protocol	Ogata, T.			27	S2	p. ii73	artikel
216	P-198 Multiple neoplasms consist of gastric cancer and hematological malignancy	Natori, K.			27	S2	p. ii57	artikel
217	P-113 Multiple neoplasms including hematological malignancies and esophageal cancer	Natori, K.			27	S2	p. ii33	artikel
218	P-262 Multivisceral resections for gastric cancer - Should all patients with locally-disease receive them?	Viapiana, P.			27	S2	p. ii76	artikel
219	P-287 Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): a randomized, open-label phase 2 study	Andrew, Dean			27	S2	p. ii84	artikel
220	P-069 Neoadjuvant chemotherapy for esophageal cancer: comparison of DCS (DTX/CDDP/S-1) chemotherapy with FAN (5-FU/ADM/Nedaplatin) chemotherapy	Shimoji, H.			27	S2	p. ii21	artikel
221	P-075 Neoadjuvant chemotherapy of esophageal cancer	Ribeiro, M.			27	S2	p. ii23	artikel
222	P-078 Neoadjuvant epirubicin, oxaliplatin and capecitabine (EOX) in locally advanced resectable gastroesophageal junction and gastric adenocarcinoma: the experience in our institution	Martínez, J.			27	S2	p. ii24	artikel
223	P-284 NESC Multicenter phase II trial in the Preoperative Treatment of gastric adenocarcinoma consisting of chemotherapy using docetaxel-cisplatin-5FU + lenograstim followed by chemoradiation (RTCT) based 5FU and oxaliplatin and surgery	Mineur, L.			27	S2	p. ii83	artikel
224	P-066 New methods of detecting oxaliplatin-induced peripheral sensory neuropathy in patients undergoing adjuvant treatment with 5-fluorouracil and oxaliplatin for colon cancer	Szpejewska, J.			27	S2	p. ii20	artikel
225	P-010 Next generation sequencing mutational analysis of primary and metastatic colorectal cancer samples in relationship to efficacy of cetuximab-based therapy	Nemecek, R.			27	S2	p. ii3	artikel
226	P-114 Non-Hodgkin's lymphoma that diagnosed from gastrointestinal biopsy	Natori, K.			27	S2	p. ii33	artikel
227	P-073 Non surgical management of oesophageal cancer-a retrospective audit with 10 year follow up	Kodavatiganti, R.			27	S2	p. ii22	artikel
228	P-058 Nutritional status and survival in elderly patients with colorectal cancer	Barao, K.			27	S2	p. ii18	artikel
229	P-152 Observational Cohort Study of 1st line Bevacizumab Combined with Chemotherapy in Metastatic Colorectal Cancer (HGCSG0802): Sub-group Analysis by the Glasgow Prognostic Score (GPS)	Miyagishima, T.			27	S2	p. ii45	artikel
230	P-056 Outcome of maintenance therapy in patients who achieved NED after liver resection for mCRC	Al-Hajeili, M.			27	S2	p. ii17	artikel
231	P-260 Outcomes of laparoscopic and open gastrectomy for gastric cancer: a comparative analysis	Castro, B.			27	S2	p. ii75	artikel
232	P-169 Outcomes of metastatic gastroesophageal cancer patients treated with third line therapy: a 5-year retrospective analysis at a single centre	Lam Justina Yick, C.			27	S2	p. ii50	artikel
233	P-173 Outcomes of palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer	Fanotto, V.			27	S2	p. ii51	artikel
234	P-128 Outcomes with watch-and-wait after pelvic radiotherapy for rectal cancer in East Kent	Sridharan, M.			27	S2	p. ii38	artikel
235	P-185 Overexpression of SIRT 6 induces apoptosis in hepatocellular carcinoma mediated by Wnt/&bgr;-catenin signaling pathway	Kim, S.M.			27	S2	p. ii54	artikel
236	P-195 Oxaliplatin-induced ocular toxicities remain overlooked	Una Cidon, E.			27	S2	p. ii57	artikel
237	P-283 Paclitaxel plus valproic acid versus paclitaxel alone as second or third line therapy for advanced gastric cancer: a randomized phase 2 trial	Kinoshita, J.			27	S2	p. ii82	artikel
238	P-126 PANOVA: a pilot study of TTFields concomitant with gemcitabine for front-line therapy of advanced pancreatic adenocarcinoma	Rivera, F.			27	S2	p. ii37	artikel
239	P-134 Parthenolide suppresses hypoxia induced angiogenesis and epithelial-mesenchymal transition by regulating hypoxia inducible factor 1 &agr; signaling in colorectal cancer	Kim, S.L.			27	S2	p. ii39	artikel
240	P-127 Pathological versus clinical complete responders after preoperative treatment in rectal cancer: long term outcomes analysis	Iseas, S.			27	S2	p. ii37	artikel
241	P-156 Pathologic response of liver metastases from colorectal cancer after chemotherapy and aflibercept: initial report of 23 cases from 9 patients	Bibeau, F.			27	S2	p. ii46	artikel
242	P-072 Pattern of recurrence and efficacy of salvage therapy after relapse in locally advanced esophageal carcinoma treated with preoperative chemoradiotherapy plus surgery	Oliva, M.			27	S2	p. ii22	artikel
243	P-279 Pembrolizumab for patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: phase 2 KEYNOTE-180 study	Manish, Shah			27	S2	p. ii81	artikel
244	P-274 Pembrolizumab for patients with previously treated, mismatch repair–deficient microsatellite instability–high advanced colorectal carcinoma: phase 2 KEYNOTE-164 study	Dung, Le			27	S2	p. ii79	artikel
245	P-280 Pembrolizumab versus physician-choice chemotherapy for previously treated patients with advanced/metastatic squamous or adenocarcinoma of the esophagus or Siewert I adenocarcinoma of the esophagogastric junction (EGJ): Randomized, phase 3 KEYNOTE-18	Toshihiko, Doi			27	S2	p. ii81	artikel
246	P-092 Perioperative chemotherapy in gastric adenocarcinoma-prognostic factors identification	Marques, C.			27	S2	p. ii27	artikel
247	P-221 PET-MR Imaging to Assess early treatment response in Pancreatic Adenocarcinoma	Collisson, E.			27	S2	p. ii64	artikel
248	P-278 Phase Ib/II study of nivolumab plus CAPIRI: Initial results of metastatic colon cancer and pancreatic adenocarcinoma patients	Khemka, V.			27	S2	p. ii80	artikel
249	P-100 Phase IB study of sorafenib + evofosfamide in patients (pts) with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC): NCCTG N1153 (Alliance)	Borad, M.			27	S2	p. ii29	artikel
250	P-121 Phase Ib trial of oxaliplatin, UGT1A1 genotype-directed dosing of irinotecan and chronomodulated capecitabine (OXIRI) chemotherapy in patients with advanced pancreatic cancer	Ng, C.			27	S2	p. ii35	artikel
251	P-081 Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for gastric cancer	Wang, G.X.			27	S2	p. ii25	artikel
252	P-052 Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancer	Osumi, H.			27	S2	p. ii16	artikel
253	P-117 Phase II study of combination chemotherapy of gemcitabine/S-1 with nafamostat mesilate for advanced unresectable pancreatic cancer. First report	Uwagawa, T.			27	S2	p. ii34	artikel
254	P-122 Phase I study of S-1, irinotecan plus oxaliplatin combination therapy (S-IROX) for Unresectable pancreatic ductal adenocarcinoma	Sasaki, M.			27	S2	p. ii36	artikel
255	P-059 Phase I trial of FOLFOXIRI in combination with Panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer (JACCRO CC-14)	Tsuji, A.			27	S2	p. ii18	artikel
256	P-231 Physical activity and Barrett's Oesophagus	Jarosz, M.			27	S2	p. ii67	artikel
257	P-008 Plasma lipidome of patients with advanced colorectal cancer	Figueiredo Jr, A.			27	S2	p. ii3	artikel
258	P-202 Preclinical assessment of the bioequivalence of branded and generic oxaliplatin and incidence of hypersensitivity reactions in patients with advanced colorectal cancer	Baratelli, C.			27	S2	p. ii58	artikel
259	P-022 Predictive biomarkers of pathologic response to preoperative chemoradiotherapy in locally advanced rectal cancer	Jankovic, R.			27	S2	p. ii7	artikel
260	P-051 Preliminary clinical and pathologic characteristics of patients treated in second-line (2L) with 25 cycles (Cy) or more of FOLFIRI + Aflibercept (FA)	Pericay, C.			27	S2	p. ii15	artikel
261	P-208 Pre-therapy physical function and body status of patients with advanced gastrointestinal cancer compared to breast cancer patients and healthy women	Stuecher, K.			27	S2	p. ii60	artikel
262	P-223 Pretreatment low skeletal muscle mass predicts clinical outcomes after chemoradiotherapy for locally advanced pancreatic cancer	Kishi, T.			27	S2	p. ii65	artikel
263	P-044 Primary anorectal melanomas: rare entity, interest of targeting CKIT	Oualla, K.			27	S2	p. ii13	artikel
264	P-029 Prognostic analysis of colon cancer patients using elastic lamina invasion and ascitic CEA	Lee, I.K.			27	S2	p. ii9	artikel
265	P-181 Prognostic factors and survival in patients with stage IV pancreatic cancer	Alexa, T.			27	S2	p. ii53	artikel
266	P-103 Prognostic factors for survival in patients with advanced intrahepatic cholangiocarcinoma treated with gemcitabine plus cisplatin as first line treatment	Ishimoto, U.			27	S2	p. ii30	artikel
267	P-048 Prognostic Impact of CA19-9 Level at Diagnosis in Resected Stage I-III Pancreatic Adenocarcinoma: a US Population Study	Mirkin, K.			27	S2	p. ii14	artikel
268	P-179 Prognostic Implication of para-aortic lymph node metastasis in pancreatic head adenocarcinoma	Kostov, D.			27	S2	p. ii53	artikel
269	P-025 Prognostic markers to predict efficacy of 5-FU rechallenge as third line chemotherapy in metastatic colorectal cancer	Chung, I.-J.			27	S2	p. ii8	artikel
270	P-098 Prognostic significance of comorbidities in elderly patients with Hepatocellular carcinoma (HCC) treated with Transarterial Chemoembolization: a Single Centre Experience	Aravind, P.			27	S2	p. ii29	artikel
271	P-013 Prognostic significance of cyclin D1 and p21 (WAF1/CIP1) in Gastric Cancer	Michalaki, V.			27	S2	p. ii4	artikel
272	P-290 Prognostic Significance of Peritoneal Lavage Cytology in Staging Gastric Cancer: Systematic Review and Meta-Analysis	Sara, Jamel			27	S2	p. ii85	artikel
273	P-005 Prognostic significance of the frequency of primary cilia in cells of small bowel and colorectal adenocarcinoma	Kupec, M.			27	S2	p. ii2	artikel
274	P-251 Prone-position thoracoscopic esophagectomy (bilateral pulmonary ventilation) for esophageal cancer with respiratory dysfunction	Michiura, T.			27	S2	p. ii73	artikel
275	P-055 Prospective evaluation for chemotherapy-induced nausea and vomiting in colorectal cancer receiving oxaliplatin-based chemotherapy of moderate emetic risk	Shimokawa, M.			27	S2	p. ii17	artikel
276	P-207 Protective Effect of Ursodeoxycholic acid in the Chemotherapy Induced Mucositis	Chun, H.J.			27	S2	p. ii60	artikel
277	P-158 Radioembolization (SIRT) as a Consolidation Treatment in Colorectal Liver Metastases after First Line Chemotherapy: Efficacy Safety	Cortesi, E.			27	S2	p. ii47	artikel
278	P-174 Ramucirumab and paclitaxel in platin refractory advanced or metastatic gastric or gastrooesophageal junction adenocarcinoma – a single center experience	Vogl, U.			27	S2	p. ii52	artikel
279	P-061 Real-world experiences of use of aflibercept in patients with stage IV colorectal cancer in the North-West of England	Flaum, N.			27	S2	p. ii19	artikel
280	P-226 Rectal Bioelectrical impedance (REBI) as a possible screening tool for colorectal cancer (CRC)	Gonzalez-Correa, C.			27	S2	p. ii66	artikel
281	P-148 Recurrence free survival as a putative surrogate for overall survival in phase III Trials of Curative – Intent Treatment of Colorectal Liver Metastases: Systematic Review	Araujo, R.			27	S2	p. ii43	artikel
282	P-153 Regorafenib in the real-life clinical practice: data from the czech registry	Buchler, T.			27	S2	p. ii45	artikel
283	P-159 Regorafenib vs TAS-102 as salvage-line treatment in patients with metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study	Kotaka, M.			27	S2	p. ii47	artikel
284	P-166 Re-hepatectomy is a predictor of long-term survival in patients that recur after liver resection of colorectal liver metastases	Marques, M.			27	S2	p. ii49	artikel
285	P-045 Resistant form of helicobacter pylori in development of stomach MALT lymphoma	Mallaev, M.			27	S2	p. ii13	artikel
286	P-269 Results of combined surgical treatment locally advanced cancer of the rectum with germination in genital organs	Abdujapparov, A.			27	S2	p. ii78	artikel
287	P-168 Retrospective comparison of efficacy and safety of docetaxel and weekly-paclitaxel as 2nd-line chemotherapy for patients with unresectable or recurrent esophageal cancer	Nakatsumi, H.			27	S2	p. ii50	artikel
288	P-211 Revisit of endoscopic ultrasonography to evaluate depth of invasion of early gastric cancer before endoscopic mucosal dissection compared with conventional endoscopy	Lee, J.S.			27	S2	p. ii61	artikel
289	P-108 Role of adjuvant treatment in periampullary carcinoma	Baghmar, S.			27	S2	p. ii32	artikel
290	P-276 Safety and Efficacy of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Patients with Chemotherapy-Naïve Metastatic Colorectal Cancer (SAPPHIRE)	Nagata, N.			27	S2	p. ii80	artikel
291	P-214 Salvage Chemoradiotherapy for Locally Recurrent Bile Duct Cancer	Yu, J.I.			27	S2	p. ii62	artikel
292	P-236 Screening practices of Australians at population and familial risk following the partial roll-out of the National Bowel Cancer Screening Program, 2009-2012	Flander, L.			27	S2	p. ii67	artikel
293	P-084 Several affecting factors of submucosal or Lymphovascular Invasion in Early Gastric Cancer Resected by Endoscopic Submucosal Dissection	Kang, D.H.			27	S2	p. ii25	artikel
294	P-249 Short-term results of surgery in elderly (>65 years) versus younger patients with Stage I-II colonic adenocarcinoma: a case-control study	Lumachi, F.			27	S2	p. ii73	artikel
295	P-043 Significance of bcl-2 in rectal cancer recurrences	Botiralieva, G.			27	S2	p. ii13	artikel
296	P-193 Significance of monitoring imatinib concentration in Gastrointestinal Stromal tumor patients	Xu, H.			27	S2	p. ii56	artikel
297	P-140 Significant intraoperative blood loss predicts poor prognosis after hepatectomy following neoadjuvant chemotherapy for liver-only colorectal metastases	Costa Neves, M.			27	S2	p. ii41	artikel
298	P-035 Simultaneous carcinoembryonic antigen (CEA), carcinoma antigen 19-9 (CA 19-9) and 125 (CA-125) measurement in patients with gastric cancer (stage IA-IB): a case-control study	Lumachi, F.			27	S2	p. ii10	artikel
299	P-102 Sorafenib after locoregional treatments for advanced or recurrent hepatocellular carcinoma	Ribeiro, C.			27	S2	p. ii30	artikel
300	P-177 Stereotactic Radiotherapy (SRT) versus Whole Brain Radiotherapy (WBRT) in the management of 1-3 brain metastases (BM) originating from a gastrointestinal (GI) tract malignancy	Lim, P.S.			27	S2	p. ii52	artikel
301	P-002 Suppression of lipocalin-2 promotes the epithelial-to-mesenchymal transition in human colorectal cancer cells	Kim, S.L.			27	S2	p. ii1	artikel
302	P-197 Surgical Emergencies in Colorectal Malignancies-Patient Profile Analysis	Thangasamy Bharathi, M.			27	S2	p. ii57	artikel
303	P-268 Surgical outcomes and strict follow-up of retroperitoneal soft-tissue sarcoma	Chiappa, A.			27	S2	p. ii77	artikel
304	P-257 Surgical treatment of patients with neuroendocrine neoplasms of the stomach	Peregorodiev, I.			27	S2	p. ii74	artikel
305	P-065 Surveillance colonoscopy after endoscopic resection of early colon cancer	Kim, J.-O.			27	S2	p. ii20	artikel
306	P-105 Surveillance CT in patients with complete remission following curative chemoradiotherapy for Anal Cancer (Single Centre experience)	Mikropoulos, C.			27	S2	p. ii30	artikel
307	P-261 Survival and disease-free survival in a consecutive monocentric series of more than 1000 D-2 gastric resection for cancer	Chiappa, A.			27	S2	p. ii75	artikel
308	P-218 Survival in incidental gallbladder cancer treated with short-course radiotherapy after simple cholecystectomy without re-exploration, and evaluation of tumor biomarkers: The experience at The National Cancer Institute (México)	Zamora Moreno, J.			27	S2	p. ii63	artikel
309	P-184 Survival patterns of positive lymph node non metastatic gastric cancer in the United States	Meshref, A.			27	S2	p. ii54	artikel
310	P-246 Survival patterns of stage IV pancreatic cancer: a population-based study	Mousa, M.			27	S2	p. ii71	artikel
311	P-129 Survival rates of patients with rectal cancer in the department for general and abdominal surgery university clinical center maribor, who underwent surgery between 2004 and 2014	Arslani, N.			27	S2	p. ii38	artikel
312	P-164 Synchronous disease does not predict long-term outcomes in patients with resected colorectal cancer liver metastases	Marques, M.			27	S2	p. ii48	artikel
313	P-239 Synchronous esophageal neoplasia among head and neck cancer patients: endoscopy surveillance and risk factor analysis	Mei-Hsuan, L.			27	S2	p. ii68	artikel
314	P-205 Synthesis and biological evaluation of Novel Heterocyclic Analogues in Cancer cell lines	Kaura, A.			27	S2	p. ii59	artikel
315	P-021 Tanshinone IIA can inhibit human pancreatic carcinoma BxPC3 cells through decreasing the protein expressions of IGFR, EGFR, VEGFR and blocking both Ras/Raf/MEK/ERK and Ras/PI3K/AKT/mTOR pathway in vitro and in vivo	Su, C.C.			27	S2	p. ii7	artikel
316	P-020 Targeting multidrug resistance – associated protein 4 (MRP4/ABCC4) in pancreatic cancer	May, M.			27	S2	p. ii6	artikel
317	P-225 The addition of oxaliplatin increases pathological complete response: a meta-analysis of randomized controlled trials on radiochemotherapy in rectal cancer	Wyrwicz, L.			27	S2	p. ii65	artikel
318	P-054 The clinical predictor of antitumor efficacy of cetuximab based regimen in first-line therapy to unresectable metastatic colorectal cancer	Tanioka, H.			27	S2	p. ii16	artikel
319	P-085 The efficacy of colonoscopy in patients with early gastric cancer who underwent endoscopic submucosal dissection	Kang, D.H.			27	S2	p. ii26	artikel
320	P-143 The evaluation of liver resection for colorectal cancer liver metastasis	Yanaga, K.			27	S2	p. ii42	artikel
321	P-151 The expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in patients with colorectal adenocarcinoma and lymph node metastases	Lumachi, F.			27	S2	p. ii44	artikel
322	P-042 The genetic profile of pancreatic circulating tumor cells	Apostolou, P.			27	S2	p. ii13	artikel
323	P-132 The impact of obesity on complete pathologic response to neoadjuvant chemoradiotherapy in rectal cancer patients	Diaz, C.			27	S2	p. ii39	artikel
324	P-192 The impact on comorbidities in deciding the dose for the first cycle of chemotherapy	Una Cidon, E.			27	S2	p. ii56	artikel
325	P-171 The impact on survival of CPT-11 as third-line or later treatment in advanced gastric cancer	Makiyama, A.			27	S2	p. ii51	artikel
326	P-272 The international, open-label, multicenter phase 2 LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients with locally advanced pancreatic cancer (LAPC)	Pascal, Hammel			27	S2	p. ii78	artikel
327	P-186 The molecular pathology characteristics of c-Kit and PDGFRA gene mutation in gastrointestinal stromal tumors in China	Zhang, B.			27	S2	p. ii55	artikel
328	P-050 The pharmacological costs of first-line therapies in unselected advanced colorectal cancer patients: a review of published phase III trials	Giuliani, J.			27	S2	p. ii15	artikel
329	P-034 The potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated by preoperative docetaxel, cisplatin, and S-1	Fushida, S.			27	S2	p. ii10	artikel
330	P-270 The results of reconstructive and plastic surgery of the pelvic floor after combined removal of retroperitoneal tumors of pelvis	Abdujapparov, A.			27	S2	p. ii78	artikel
331	P-070 The risk of thromboembolic events in upper GI cancer patients undergoing preoperative chemotherapy	Mohan Annet Jesmine, M.			27	S2	p. ii21	artikel
332	P-135 The role of Angiotensin II subtype IA receptor on liver metastasis formation	Shimizu, Y.			27	S2	p. ii39	artikel
333	P-037 The role of carcino-embryonic antigen testing among western patients with resected gastric cancer	Greenleaf, E.			27	S2	p. ii11	artikel
334	P-210 The role of F-18 fluorodeoxyglucose PET/CT for detecting recurrence in asymptomatic gastric patients after curative resection	Lee, J.W.			27	S2	p. ii61	artikel
335	P-233 The role of molecular biomarker CDKN-2A in early diagnosis of colorectal cancer	Ten, Y.			27	S2	p. ii67	artikel
336	P-232 The value of echinococcosis in development of liver cancer	Almanova, A.			27	S2	p. ii67	artikel
337	P-082 Three years of metastatic gastric cancer follow up in our hospital	Ferrer, M.			27	S2	p. ii25	artikel
338	P-204 Toxicological and biochemical assessment of specific COX-2 inhibitor as adjuvant in fluoropyrimidine therapy in chemically induced colon cancer	Goel, H.			27	S2	p. ii59	artikel
339	P-190 Treating fatigue in patients with colorectal cancer (CC)	Heras, P.			27	S2	p. ii56	artikel
340	P-141 Treatment approaches for resectable colorectal cancer metastases in the liver exhibiting poor prognosis	Lazarev, A.			27	S2	p. ii41	artikel
341	P-252 Treatment of locally advanced adenocarcinoma of the esophagogastric junction type I	Kostov, D.			27	S2	p. ii73	artikel
342	P-216 Treatment of squamous cell anal cancer with IMRT and simultaneous hypofractionated boost combined with concurrent chemotherapy	Diaz Gomez, L.			27	S2	p. ii62	artikel
343	P-011 Tumor budding is associated with low expression of miRNA-148a and miRNA-625-3p in colorectal cancer	Baltruskeviciene, E.			27	S2	p. ii3	artikel
344	P-030 Tumor-infiltrating lymphocytes (TILs) density as prognostic determinant in stage II colorectal cancer	Ricci, V.			27	S2	p. ii9	artikel
345	P-243 Undiagnosed chronic liver disease (CLD) in patients presenting with Hepatocellular Carcinoma (HCC)	Spiliopoulou, P.			27	S2	p. ii70	artikel
346	P-155 Unresectable colorectal cancer liver metastases: retrospective review and survival analysis	Calera Urquizu, L.			27	S2	p. ii46	artikel
347	P-053 Updated analysis of induction & maintenance adjuvant chemotherapy with 3-month oxaliplatin-based regimen followed by 3 months capecitabine in patients with stage III and high-risk stage II colorectal cancer :(JSWOG C2)	Tanioka, H.			27	S2	p. ii16	artikel
348	P-019 Use of serum levels of cytokine TGF &bgr;1 in detection of Hepatocellular carcinoma in patients with chronic liver disease	Mehmedovic, A.			27	S2	p. ii6	artikel
349	P-091 Validation of Functional Assessment of Cancer Therapy-Gastric (FACT-Ga) and its sensitivity to ascites volume change: an analysis of two Japanese clinical trials	Maeda, H.			27	S2	p. ii27	artikel
350	P-240 Vitamin D levels in oesophageal and gastric cancer patients and their outcome	Thanthulage, S.			27	S2	p. ii68	artikel
351	P-112 Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer	Kumari, P.			27	S2	p. ii33	artikel
352	P-115 Weight loss during 1st-line chemotherapy for upper gastrointestinal malignancies (UGI) may impact survival and access to further treatment lines	Oikonomopoulos, G.			27	S2	p. ii34	artikel
353	P-258 5-Year survival of gastric cancer patients after radical surgery was significantly depended on tumor characteristics, blood cell circuit, cell ratio factors, hemostasis system and adjuvant treatment	Kshivets, O.			27	S2	p. ii75	artikel
354	P-247 Young patients under 40 age with colorectal cancer have poor survival	Kumari, P.			27	S2	p. ii71	artikel
355	RM-053 A clinico epidemiological study of non metastatic gastrointestinal stromal tumor: a prospective observational multi institutional study from Southern India	Rathnam, K.			27	S2	p. ii98	artikel
356	RM-030 A Compartive Study of Capecitabine and Oxaliplatin versus 5-fluorouracil in Neoadjuvant Chemoradiation for Locally Advanced Rectal Carcinoma	Soliman, A.			27	S2	p. ii92	artikel
357	RM-034 A monocentric retrospective data from 2005 to 2009 in colon-rectal cancer: an analysis in clinical practice experience	Traverso Elena, S.			27	S2	p. ii94	artikel
358	RM-054 Barrett's esophagus-associated neoplasia	Sadykov, R.			27	S2	p. ii98	artikel
359	RM-042 Biliary tract cancer: a retrospective study	Zemmour, A.			27	S2	p. ii95	artikel
360	RM-035 Can resectability conversion in patients with metastatic colon-rectal cancer to liver improve survival?	El-Nagar, A.			27	S2	p. ii94	artikel
361	RM-004 Capecitabine and oxaliplatin (XEOLX) in adjuvant gastric cancer	Bounedjar, A.			27	S2	p. ii87	artikel
362	RM-025 Chemoradiation for unresectable gall bladder cancer: regional cancer centre study	Kumari, P.			27	S2	p. ii91	artikel
363	RM-007 Chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone before surgery in patients with rectal cancer, experience of Medical Center 20 de Noviembre Mexico City	Mora Perez, J.			27	S2	p. ii87	artikel
364	RM-009 Clinical differences between right and left colonic cancer	El Bastawisy, A.			27	S2	p. ii88	artikel
365	RM-056 Clinic features of gastric neuroendocrine tumors: a single-center analysis	Balli, G.			27	S2	p. ii98	artikel
366	RM-015 Clinicopathological, epidemiological and outcome of treatment of advanced gastric cancer in Egypt: single institution experience	Gaballah, A.			27	S2	p. ii89	artikel
367	RM-049 Colorectal cancer in Indonesia - a centre report	Widjaja, S.			27	S2	p. ii97	artikel
368	RM-057 Colorectal carcinoma with liver metastases-combined versus staged resection-results of a tertiary level hospital in India	Chauhan, V.			27	S2	p. ii99	artikel
369	RM-020 Complex approach in treatment of retroperitoneal fibrosarcoma	Ulmasov, F.			27	S2	p. ii90	artikel
370	RM-060 Correlation of clinicopathological parameters with presence of human epidermal growth factor receptor in adenocarcinoma of stomach	Kandel, B.			27	S2	p. ii99	artikel
371	RM-023 Epidemiology and clinical aspects of the canal anal cancer	Zemmour, A.			27	S2	p. ii91	artikel
372	RM-027 Epidemiology, treatment and outcome of pancreatic cancer in Tunisia	Nasri, M.			27	S2	p. ii92	artikel
373	RM-043 Eruptive seborrheic keratosis (ESK) and its association with gastrointestinal cancer (GIC): a case-control study and meta-analysis	Insuasty, J.			27	S2	p. ii95	artikel
374	RM-051 Evidence-based assessment of the burden of infection related solid tumors	El-Nagar, A.			27	S2	p. ii97	artikel
375	RM-028 Gemcitabine in combination with capecitabine compared with gemcitabine combined with erlotinib in locally advanced or metastatic pancreatic cancer	Khatri, P.			27	S2	p. ii92	artikel
376	RM-001 Her -2 over–expression in gastric carcinoma in Lagos: a 5 years retrospective study	Onyekwelu, V.			27	S2	p. ii86	artikel
377	RM-065 High or low ligation of the inferior mesenteric artery during curative surgery for rectal cancer	Zedan, A.			27	S2	p. ii100	artikel
378	RM-066 Histological diagnosis of gastric submucosal tumors after endoscopic submucosal dissection	Kuryk, O.			27	S2	p. ii101	artikel
379	RM-008 Intraoperative sentinel lymph node positivity by methylene blue dye and its association with other dissected lymph node by histopathological examination in colorectal cancer	Thangasamy Bharathi, M.			27	S2	p. ii87	artikel
380	RM-010 Irinotecan and oxaliplatin-based regimens in metastatic colorectal cancer and optimization of sequence: a regional cancer center study	Kumari, P.			27	S2	p. ii88	artikel
381	RM-050 Lifestyle habits and dietary patterns in gastric cancer patients in Toungoo, Myanmar	Nwe, K.			27	S2	p. ii97	artikel
382	RM-013 Locally advanced esophageal cancer – evaluation of response with addition of neoadjuvant chemotherapy prior to chemoradiation	Saha, S.			27	S2	p. ii89	artikel
383	RM-046 Local staging of rectal cancer: diagnostic potential of endorectal contrast agent and MPRs with 64-MDCT compared with the pathologic staging	Mohran, T.			27	S2	p. ii96	artikel
384	RM-055 Long–term results of surgical treatment of gastric cancer with germination the pancreas	Yakubbekova, S.			27	S2	p. ii98	artikel
385	RM-036 Metastatic gastric adenocarcinoma	Belmadi, M.			27	S2	p. ii94	artikel
386	RM-037 Modified GTX second-line therapy in pancreatic adenocarcinoma	Temraz, S.			27	S2	p. ii94	artikel
387	RM-002 Molecular characterization of gastrointestinal stromal tumours (GISTs): the experience of Hassan II University Hospital- Fez; Morocco	Doumbia Hamidou, D.			27	S2	p. ii86	artikel
388	RM-012 Multidisciplinary management of advanced carcinoma esophagus	Behera, M.			27	S2	p. ii88	artikel
389	RM-032 Neoadjuvant chemoradiotherapy and chemotherapy in patients with locally advanced rectal cancer	Soliman, A.			27	S2	p. ii93	artikel
390	RM-063 Neoadjuvant chemotherapy for unresectable carcinoma gall bladder: our experience	Bhoriwal, S.			27	S2	p. ii100	artikel
391	RM-003 Neoadjuvant chemotherapy on advanced gastric carcinoma	Zemmour, A.			27	S2	p. ii86	artikel
392	RM-038 Neo-adjuvant FOLFIRINOX in borderline-resectable/locally advanced pancreatic adenocarcinoma	Temraz, S.			27	S2	p. ii95	artikel
393	RM-048 Neoadjuvant radiochemotherapy in advanced rectal cancer: results of a retrospective study, sphincter preservation rate	Ayad, M.			27	S2	p. ii97	artikel
394	RM-021 Neuroendocrine tumors of the Duodenum: case series from North Eastern India	Chawla, T.			27	S2	p. ii91	artikel
395	RM-029 Outcome of continuous infusion of low dose gemcitabine in locally advanced and metastatic pancreatic carcinoma	Ali Elsayed, M.			27	S2	p. ii92	artikel
396	RM-026 Palliative therapy in unresectable advanced gall bladder cancer A	Khatri, P.			27	S2	p. ii91	artikel
397	RM-005 Pancreatic adenocarcinoma in young adults in a Moroccan population	Ziani, F.			27	S2	p. ii87	artikel
398	RM-052 Pancreatic cancer – our experience	Abdallah, R.			27	S2	p. ii98	artikel
399	RM-018 Precise selection of metastatic gastric cancer patients for first line, docetaxel based chemotherapy: a retrospective study	Khatri, P.			27	S2	p. ii90	artikel
400	RM-045 Pre-operative diagnosis in pancreatic tumors-reality or myth?	Thangasamy Bharathi, M.			27	S2	p. ii96	artikel
401	RM-031 Preoperative short course chemoradiation with consolidation chemotherapy and delayed surgery in locally advanced rectal cancer	Sotoudeh, S.			27	S2	p. ii93	artikel
402	RM-044 Primitive melanoma anorectal: a report 6 cases	Yekrou, D.			27	S2	p. ii96	artikel
403	RM-016 Prognostic factors and assessment of postoperative chemoradiotherapy in gastric cancer	Mghirbi, F.			27	S2	p. ii89	artikel
404	RM-033 Rectal cancer in patients younger than 40 at AUBMC: tumor characteristics and comparative survival and disease free survival	Hakim, A.			27	S2	p. ii93	artikel
405	RM-041 Risk of selected gastrointestinal toxicities in cancer patients treated with Pazopanib: a systematic review and meta-analysis	Abdallah, L.			27	S2	p. ii95	artikel
406	RM-047 Role of CT guided celiac neurolysis in treating intractable pain from advanced primary hepatocellular carcinoma	Bessar, A.			27	S2	p. ii96	artikel
407	RM-011 Safety and efficacy of biweekly cetuximab based chemotherapy for patients with metastatic colorectal cancer	Zekri, J.			27	S2	p. ii88	artikel
408	RM-024 Survival analysis of post-operatively treated cancer gall bladder patients with Adjuvant Chemo-radiotherapy: an institutional study	Saugat, S.			27	S2	p. ii91	artikel
409	RM-017 Systemic chemotherapy in advanced gastric carcinoma: a comparison of docetaxel, cisplatin and fluorouracil (DCF) versus cisplatin and fluorouracil (CF); versus epirubicin, cisplatin and fluorouracil (ECF) regimens in clinical setting, a retrospective study	Kumari, P.			27	S2	p. ii90	artikel
410	RM-059 The effect of adjuvant chemotherapy following extended gastrectomy for Siewert's type II adenocarcinoma of the esophagogastric junction	Bayramov, R.			27	S2	p. ii99	artikel
411	RM-014 The multidisciplinary approach for gastrointestinal stromal tumors (GIST) with hepatic metastases: a retrospective study of 33 patients	Zhang, B.			27	S2	p. ii89	artikel
412	RM-058 Thoracolaproscopic esophagectomy for carcinoma esophagus: our early experience and outcome	Karuupasamy, S.			27	S2	p. ii99	artikel
413	RM-064 Total mesorectal excision for the treatment of rectal cancer	Zedan, A.			27	S2	p. ii100	artikel
414	RM-019 Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: feasibility of hepatic resection	Kadirov, K.			27	S2	p. ii90	artikel
415	RM-061 Treatment outcomes of gall bladder cancer, 10 years experience	Zedan, A.			27	S2	p. ii100	artikel
416	RM-006 Youthful age enhances threat of lymph node positivity in early-stage rectal cancer in Albania	Enkelejda, S.			27	S2	p. ii87	artikel
417	Table of Contents				27	S2	p. v	artikel
418	Title Page				27	S2	p. iv	artikel

418 gevonden resultaten

Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland